Berlin

• A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations Recruiting
  2023-506759-51-00 7 2024-03-29 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting
  2023-503376-24-00 5 2024-03-20 Metastatic non-small cell lung cancer (NSCLC)
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting
  2023-504472-24-00 4 2024-03-19 Early Idiopathic Parkinson’s disease (PD)
• DOUBLE PRO-TECT Alport: A confirmatory, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the effect of Dap … Recruiting
  2023-508502-18-00 5 2024-03-19 Alport syndrome
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho … Recruiting
  2023-505141-48-00 5 2024-03-07 Fibrosis
• A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in C … Recruiting
  2023-507611-35-00 1 2024-03-01 mild to moderate asthma
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul … Recruiting
  2023-504863-17-00 5 2024-02-21 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus
• An Open-label Study of XEN1101 in Epilepsy Recruiting
  2022-502282-24-00 5 2024-02-14 Primary generalized tonic-clonic seizures
• Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
  2023-506604-18-00 1 2024-02-14 Triple negative breast cancer
• Randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety and tolerability of givinostat in non-ambul … Recruiting
  2023-503521-19-00 5 2024-02-09 Duchenne muscular dystrophy (DMD)
• A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with u … Recruiting
  2023-507547-11-00 1 2024-02-09 Ulcerative colitis
• Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation Recruiting
  2023-504146-60-00 10 2024-02-07 lymphatic malformations associated with PIK3CA mutation
• Treatment of Established Status Epilepticus in the Elderly - a prospective, randomized, double-blind comparative effectiveness trial Recruiting
  2024-516634-35-00 6 2024-02-01 Convulsive or nonconvulsive benzodiazepine-resistant (established) sta
• Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting
  2023-503327-26-00 5 2024-01-31 Sjogren's syndrome
• Clinical and translational controlled study of Perampanel treatment around Surgery in patients with progressive glioblastoma (PerSurge) Recruiting
  2023-503938-52-00 4 2024-01-26 Progressive Glioblastoma
• Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra … Recruiting
  2023-504141-31-00 4 2024-01-17 Metastatic HR positive, HER2 negative breast cancer
• First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in pat … Recruiting
  2022-503084-15-00 1 2024-01-12 Progressive metastatic solid cancer after failure of established treat
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac … Recruiting
  2022-502046-28-00 5 2023-12-22 HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
• Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer Recruiting
  2024-515127-11-00 4 2023-12-21 hepatocellular carcinoma
• A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily … Recruiting
  2022-502950-14-00 6 2023-12-08 Partial Lipodystrophy
• Prophylaxis Study of Marstacimab in Pediatric Hemophilia Participants With or Without Inhibitors Recruiting
  2022-500495-65-00 5 2023-12-06 Haemophilia
• 24 weeks double-blind randomized placebo-controlled trial to evaluate efficacy, PK, safety of LOU064 in adolescents (12 - <18) with CSU and … Recruiting
  2022-502159-78-00 5 2023-12-06 Chronic Spontaneous Urticaria

Showing 697–720 of 1,776 trials